2023 World Conference on Lung Cancer (Posters)-EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era

EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era - PDF(Slides)

Back to course

Pdf Summary

A retrospective study conducted at San Bortolo General Hospital in Vicenza, Italy, examined the impact of the introduction of chemoimmunotherapy on the survival of patients with extensive-stage small cell lung cancer (ES-SCLC). The study included all ES-SCLC patients who received platinum-etoposide chemotherapy between November 2017 and March 2023. The primary aim was to compare clinical indicators before and after the introduction of atezolizumab, an immunotherapy drug, in July 2020.<br /><br />The study included a total of 51 patients, with 20 treated before July 2020 and 31 treated after. The median age was 64 years, and 67% of the patients were male. The patients treated after the introduction of atezolizumab had a higher eligibility for immunotherapy. <br /><br />The results showed that patients treated with chemoimmunotherapy had improved survival outcomes compared to those who received chemotherapy alone. The 12-month overall survival rate was 23.8% for the chemoimmunotherapy group, compared to 9.8% for the chemotherapy-only group. The 6-month progression-free survival rate was 14.7% for the chemoimmunotherapy group, compared to 0% for the chemotherapy-only group. The median progression-free survival was 5.4 months for the chemoimmunotherapy group and 4.9 months for the chemotherapy-only group.<br /><br />The study also found that patients who received chemoimmunotherapy required fewer cycles of chemotherapy on average. The safety profile of the combination treatment was consistent with previous reports, with immune-related adverse events observed in a small percentage of patients.<br /><br />In conclusion, the study provides evidence of the tolerability and clinical effectiveness of chemoimmunotherapy in the treatment of ES-SCLC. The addition of immunotherapy improved survival outcomes and reduced the need for chemotherapy in these patients. Further research is needed to identify predictive biomarkers for better patient selection.

Asset Subtitle

Lorenzo Calvetti

Meta Tag

Speaker Lorenzo Calvetti

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

retrospective study

San Bortolo General Hospital

Vicenza

Italy

chemoimmunotherapy

extensive-stage small cell lung cancer

ES-SCLC

platinum-etoposide chemotherapy

atezolizumab

immunotherapy drug